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OBJECTIVE—To test whether induction of chimerism lowers
the amount of donor islets required for reversal of diabetes and
renders the pancreas a suitable site for islet grafts in autoimmune
diabetic mice.
RESEARCH DESIGN AND METHODS—The required donor
islet dose for reversal of diabetes in late-stage diabetic NOD mice
after transplantation into the liver or pancreas was compared
under immunosuppression or after induction of chimerism. Re-
cipient mice were monitored for blood glucose levels and mea-
sured for insulin-secretion capacity. Islet grafts were evaluated
for -cell proliferation, -cell functional gene expression, and
revascularization.
RESULTS—With immunosuppression, transplantation of 1,000,
but not 600, donor islets was able to reverse diabetes when
transplanted into the liver, but transplantation of 1,000 islets was
not able to reverse diabetes when transplanted into the pancreas.
In contrast, after induction of chimerism, transplantation of as
few as 100 donor islets was able to reverse diabetes when
transplanted into either the liver or pancreas. Interestingly, when
lower doses (50 or 25) of islets were transplanted, donor islets in
the pancreas were much more effective in reversal of diabetes
than in the liver, which was associated with higher -cell
replication rate, better -cell functional gene expression, and
higher vascular density of graft islets in the pancreas.
CONCLUSIONS—Induction of chimerism not only provides
immune tolerance to donor islets, but also markedly reduces the
required amount of donor islets for reversal of diabetes. In
addition, this process renders the pancreas a more superior site
than the liver for donor islets in autoimmune mice. Diabetes 59:
2228–2236, 2010
T
ype 1 diabetes results from autoimmune destruc-
tion of insulin-secreting pancreatic -cells (1). A
cure for type 1 diabetes will require a reversal of
autoimmunity as well as regeneration or replace-
ment of islet -cells (2,3). Currently, islet transplantation
is the only therapy with the potential to reverse refractory
late-stage type 1 diabetes in animal models and patients
(4), although hundreds of regimens have been reported to
prevent type 1 diabetes (3), and anti-CD3 therapies have
been shown to reverse or ameliorate new-onset type 1
diabetes in mouse models or patients (5–8). However, islet
transplantation under the current Edmonton protocol of
administration of immunosuppressants, including rapamy-
cin, tacrolimus, and anti-IL-2 mAb, only provides insulin
independence for 1 to 2 years in most recipients (9).
The obstacles that prevent islet transplantation as a
curative therapy for refractory late-stage type 1 diabetes
include: 1) chronic rejection of islet grafts mediated by
allo- and autoimmunity (10,11); 2) chronic toxicity of
immunosuppressants and their impairment of islet graft
function and -cell regeneration (12–14); 3) limited avail-
ability of donor islets (e.g., under the Edmonton protocol,
more than two cadaveric donors are usually required for
each recipient, which limits the widespread application of
islet transplantation); and 4) lack of an ideal graft site. For
instance, in current clinical islet transplantation, donor
islets are usually injected via the portal vein into the liver.
Unfortunately, this procedure has shortcomings. First,
portal vein injection of islets can cause bleeding, throm-
bosis, and portal system hypertension. Second, studies
with syngeneic islet transplantation in animal models have
shown that islet grafts in the liver, but not in the pancreas,
demonstrate signiﬁcant dysfunction 1 month after trans-
plantation (15,16). Third, glucagon secretion has been
found to be defective in response to insulin-induced
hypoglycemia in some patients with islet grafts in the liver,
although islet transplantation has impressively decreased
the number and severity of episodes of hypoglycemia
(17,18). As one alternative, the pancreas itself could pro-
vide a site for donor islets; however, it is still unknown
whether the pancreas of an autoimmune individual can be
a graft site for donor islets. Taken together, a regimen that
can overcome each of these obstacles could promote islet
transplantation as a curative therapy for refractory type 1
diabetes.
Induction of mixed chimerism is one of the most effec-
tive approaches for induction of organ transplantation
tolerance (19), and this concept has been recently demon-
strated in humans (20–22). In addition, the induction of
chimerism is also effective in reversal of autoimmunity in
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cently reported that induction of chimerism under a
radiation-free and graft versus host disease (GVHD) pre-
ventive anti-CD3-based conditioning regimen led to rever-
sal of autoimmunity and elimination of insulitis (2,27).
Beyond this, it has been reported that adult -cells can
replicate to reverse hyperglycemia in nonautoimmune
mice (12). In addition, we have observed that after
elimination of insulitis by induction of chimerism, re-
sidual islet -cells in the pancreas proliferated to re-
verse diabetes in new-onset, although not in late-stage,
diabetic NOD mice (2).
In the current study, we tested whether induction of
chimerism under the radiation-free anti-CD3-based condi-
tioning regimen lowers the amount of donor islets required
for reversal of diabetes and whether the pancreas would
provide a suitable site for islet grafts in late-stage diabetic
NOD mice. Herein, we have demonstrated that, after
induction of chimerism, the required amount of donor
islets for reversal of diabetes was markedly reduced when
transplanted into the liver or pancreas. In addition, our
studies suggest that after induction of chimerism, the
pancreas may provide a superior site for donor islets in
comparison with the liver, as assessed by enhanced -cell
replication, better long-term -cell function, and improved
revascularization of the graft islets in the pancreas.
RESEARCH DESIGN AND METHODS
Female NOD/LtJ (H-2
g7) and FVB/N (H-2
q) mice were purchased from Jackson
Laboratory (Bar Harbor, ME). The luciferase transgenic (Luc
) FVB/N line
was generated as previously described (28). All animals were maintained in a
pathogen-free room at City of Hope Research Animal Facilities (Duarte, CA).
The animal-use procedures were approved by the Institutional Committee of
City of Hope.
Immunosuppressant therapy. Late-stage (3 weeks after onset) diabetic
NOD mice were given Edmonton protocol of chemotherapy before islet
transplantation, including administration of rapamycin (i.p. 2 mg/kg daily, LC
Laboratories, MA), tacrolimus (i.p. 0.6 mg/Kg daily, LC Laboratories, Woburn,
MA), and anti-mouse-IL-2 mAb (i.p. 0.5 mg/mouse weekly, S4B6–1).
Bone marrow transplantation. These procedures were described in our
previous publications (2,29) and in the supplementary materials and methods,
available in an online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db10-0450/DC1.
Isolation of islets, islet transplantation, in vivo and ex vivo biolumi-
nescent imaging, insulin level, and glucose tolerance test. These proce-
dures have been described in publications of ours and others (2,29,30) and in
the supplementary materials and methods.
Histopathology of pancreatic islets, bromodeoxyuridine labeling and
sequential chlorodeoxyuridine (CLDU) and iododeoxyuridine (IDU)
labeling of proliferating -cells and immunoﬂuoresent staining. These
procedures have been described in publications of ours and others (2,27,31)
and in the supplementary materials and methods.
Measurement of gene expression levels of the retrieved islet grafts.
Retrieving graft islets from the liver and pancreas were performed as
described previously (32,33). The primers used for real-time PCR measure-
ment of gene expression levels of luciferace, insulin, pancreatic duodenal
homeobox-1 (PDX-1), GLUT2, glucokinase (GCK), and glucagon were de-
scribed by others (34,35), and real-time PCR was performed as described in
our previous publications (36) and in the supplementary materials and
methods.
Evaluation of vascular density. Sections were stained for lectin from
Bandeiraea simplicifolia (Sigma) followed by Texas Red conjugated Strepta-
vidin (Jackson ImmunoResearch). Vascular density was identiﬁed and evalu-
ated as previously described (37,38) and in the supplementary materials and
methods.
Amylase test. Amylase activity was measured by EnzChek Ultra Amylase
Assay Kit (E33651; Molecular Probes) following the manufacturer’s protocol.
Statistical Analysis. Comparison of changes of serum blood glucose levels
after hematopoietic cell transplantation (HCT) was evaluated by the log-rank
test (Prism, version 4.0, GraphPad, San Diego, CA). Comparison of kinetic
blood glucose change in glucose tolerance test (GTT) test was evaluated with
two-way ANOVA. Comparison of means among multiple groups was evaluated
with one-way ANOVA; comparison of two means was performed with
two-tailed Student t test.
RESULTS
A large amount of donor islets that could reverse
diabetes when implanted in the liver did not reverse
diabetes when implanted in the pancreas in late-
stage diabetic NOD mice under immunosuppressant
therapy. It was reported that islet grafts functioned better
in the pancreas than in the liver in nonautoimmune
recipients (15,16). However, it is not yet clear whether the
pancreas of the autoimmune recipients can be used as a
site of donor islets. Under immunosuppressant therapy,
600 or 1,000 donor islets were required to reverse diabetes
in diabetic NOD mice (39,40). Therefore, we transplanted
600 or 1,000 donor islets into the liver or pancreas of the
late-stage diabetic NOD mice, while immunosuppressant
therapy of Edmonton protocol was used to prevent graft
rejection. Harvesting 1,000 islets required 5 donors be-
cause the average yield in our studies was 209  8 per
donor (mean  SE, N  20), which was similar to a
previous report (41). We observed that although 1,000
donor islets implanted in the liver were able to reverse
diabetes in all (6 of 6) of the recipients, the same amount
of donor islets implanted in the pancreas did not reverse
diabetes (0 of 6) (P  0.001, Fig. 1A and B). Lowering the
donor islet dose to 600 in the liver also resulted in an
inability to stably reverse diabetes (Fig. 1A). These results
indicate that under this form of immunosuppressant ther-
apy, the pancreas of the autoimmune NOD mice is not a
suitable site for donor islets.
Induction of chimerism not only markedly reduced
the required donor islet dose for reversal of late-
stage diabetes, but also rendered the pancreas of the
autoimmune NOD mice a suitable site for islet grafts.
We previously reported that induction of chimerism re-
sulted in reversal of autoimmunity, elimination of insulitis,
and immune tolerance to donor islets when implanted
under the kidney capsule (2). Therefore, we tested
whether the pancreas of the chimeric diabetic NOD recip-
ients could be a suitable site for islet grafts. Accordingly,
late-stage diabetic NOD mice were induced to develop
chimerism by conditioning with anti-CD3/CD8 along with
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FIG. 1. Transplantation of a large number of donor islets was needed to
reverse diabetes in immunosuppressant-treated late-stage diabetic
NOD mice. Late-stage diabetic NOD mice were transplanted with 1,000
or 600 islets from FVB/N mice into the liver (A) or the pancreas (B)
after the mice were given immunosuppressant therapy. The recipients
were monitored twice weekly for blood glucose for 30 days after
transplantation. For recipients with 600 donor islets in the liver or
1,000 donor islets in the pancreas, exogenous insulin was used to
ensure the survival of the recipients after transplantation. If a recip-
ient’s blood glucose was >500 mg/dl, the mouse was injected with
insulin (1 unit daily) for the subsequent 5 days, and injections were
stopped 2 days before blood glucose measuring. There were 6 recipi-
ents in each group.
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 T-depleted spleen cells and
bone marrow cells (50  10
6 each), as described in
RESEARCH DESIGN AND METHODS and in our previous publica-
tion (2). Next, 600 donor islets, which did not reverse
diabetes in the late-stage diabetic NOD mice under the
above mentioned immunosuppressant therapy, were
transplanted into the pancreas or liver of the chimeric
recipients on the next day after injection of donor bone
marrow cells. We found that 100% (6 of 6) of the chimeric
recipients with 600 donor islets in the pancreas or liver
showed normal glycemia for 120 days, although they all
had hyperglycemia (500 mg/dl) before islet transplanta-
tion (Fig. 2A). The chimeric late-stage diabetic NOD mice
without islet transplantation continued to have hypergly-
cemia, and the chimeric recipients with islet grafts under
kidney capsule showed hyperglycemia again after ne-
phrectomy (supplementary Fig. 1). Next, we titrated down
the amount of donor islets and transplanted 300, 200, and
100 donor islets into the pancreas or liver of the chimeric
recipients. We found that transplantation of 100 or more
donor islets was able to reverse hyperglycemia in all the
recipients (Fig. 2A–D).
In addition, we found that transplantation of 100 islets
from syngeneic NOD mice was also able to reverse
late-stage diabetes in the chimeric NOD mice in which
pre-existing insulitis cleared up after transplantation.
Furthermore, the chimeric recipients rapidly rejected the
islets from third-party donors when implanted in the
pancreas (supplementary Fig. 2). These results indicate
that the chimeric recipients are tolerant to both donor- and
host-type graft islets in the pancreas. Taken together,
induction of chimerism not only reverses autoimmunity
and provides immune tolerance to donor islets, but also
markedly reduces the required amount of donor islets for
reversal of diabetes and renders the pancreas a suitable
site for islet grafts.
Small amounts of donor islets implanted in the pan-
creas were more effective in reversing diabetes than
in the liver after induction of chimerism. Next, we
further titrated down the dose of donor islets to 50 and 25
islets per chimeric recipient. We observed that although 50
islets implanted in the pancreas resulted in long-term
reversal of diabetes in 70% (7 of 10) chimeric recipients, 50
islets implanted in the liver resulted in long-term reversal
in only 20% (2 of 10) of the chimeric recipients (P  0.01,
Fig. 2E). We should point out that some of the chimeric
recipients with 50 donor islets in the liver showed tran-
sient normal glycemia and relapse of hyperglycemia. This
relapse of hyperglycemia was not caused by graft rejec-
tion, because there was still strong bioluminescent imag-
ing (BLI) signaling of the islet grafts, and no inﬁltration
observed in the grafts (supplementary Fig. 3). In addition,
40% (4 of 10) of the chimeric recipients with 25 donor
islets in the pancreas reached normal glycemia, although it
took 2 months for some recipients. In contrast, none (0
of 10) of the chimeric recipients with 25 donor islets in the
liver reached normal glycemia (P  0.01, Fig. 2F). These
results indicate that when small amounts of donor islets
are transplanted, the pancreas is a better site than the liver
for islet grafts.
Graft islet -cells in the pancreas had better long-
term function than those in the liver. It has been
reported that, in a syngeneic transplantation, islet grafts in
the liver showed reduced capacity of insulin production
compared with grafts in the pancreas (15). Thus, 120 days
after islet transplantation, we compared the insulin secre-
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FIG. 2. A small number of donor islets was needed to reverse diabetes
in chimeric late-stage diabetic NOD mice. Late-stage diabetic NOD mice
were injected with BM and CD4
 T-depleted spleen cells from FVB/N
donors to induce chimerism after conditioning with anti-CD3 and
anti-CD8. The next day after HCT, titrated numbers (600–25) of islets
from FVB/N donors were transplanted into the pancreas or liver of the
chimeric recipients (A–F). The recipients were checked weekly for
blood glucose for 120 days after islet transplantation. For recipients
with 25 donor islets, exogenous insulin was used soon after transplan-
tation to ensure the survival of the recipients. If a recipient’s blood
glucose was >500 mg/dl, the mouse was injected with insulin (1 unit
daily) for the subsequent 5 days, and injections were stopped 2 days
before blood glucose measuring. There were 6–10 recipients in each
group.
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long-term chimeric recipients by GTT. We found that there
was no signiﬁcant difference in changes of serum blood
glucose or insulin levels in long-term recipients trans-
planted with 600 donor islets in the pancreas or liver
during GTT (Fig. 3A). However, the recovery rate of serum
blood glucose in recipients with 100 graft islets in the liver
was signiﬁcantly slower than that of recipients with 100
islets in the pancreas, especially at 15–90 min after glucose
injection (P  0.01, Fig. 3B). Similarly, the serum insulin
levels of recipients with 100 graft islets in the liver was
twofold lower than that of recipients with 100 graft islets
in the pancreas 5 min after glucose injection (P  0.01, Fig.
3B). In addition, although there was no signiﬁcant differ-
ence in the blood glucose recovery rate or serum insulin
levels between recipients with 600 and 100 graft islets in
the pancreas (Fig. 3C), there was a signiﬁcant difference
between recipients having 600 or 100 graft islets in the
liver (P  0.01, Fig. 3D). These results indicate that 1) islet
grafts in the pancreas may maintain better long-term
function than those in the liver; and 2) islet grafts in the
pancreas may expand better than those in the liver when
small amounts of donor islets are transplanted.
To determine whether long-term islet grafts in the
pancreas maintained superior function to those in the
liver, we retrieved islets from the pancreas and liver as
previously described (33), and identiﬁed the donor islets
with ex vivo BLI (supplementary Fig. 4). We compared the
expression levels of metabolic genes of islet grafts using
donor islet-speciﬁc luciferase mRNA as an internal control
to avoid the inﬂuence of differences in the purity of the
retrieved islets. We found that although the expression
levels of insulin, PDX-1, and GLUT2 by islet grafts from the
pancreas were similar to those before transplantation (P 
0.1; Fig. 4), the expression levels of those genes by islet
grafts from the liver was reduced by 5- to 10-fold (P 
0.01; Fig. 4). The expression levels of glucagon by islet
grafts from the liver were not different from islet grafts
from the pancreas or from those before transplantation
control (P  0.1; Fig. 4). These results indicate that
long-term graft islet -cells in the liver, but not in the
pancreas, become defective in functional gene expression.
Graft islet -cells replicated better in the pancreas
than in the liver. We previously reported that residual
islets in new-onset diabetic NOD mice could proliferate to
reverse diabetes after induction of chimerism (2). We
tested whether graft islet -cells could also proliferate in
the pancreas of the chimeric recipients. Accordingly, the
chimeric recipients with donor islet grafts in the pancreas
or liver were injected intraperitoneally with bromode-
oxyuridine (BrdU) (50 	g/g body weight) for 2 weeks
immediately after islet transplantation. The islet grafts
were identiﬁed by in vivo and ex vivo BLI (Fig. 5A). We
found that -cells in grafts from both pancreas and liver
proliferated, as determined by incorporation of BrdU, but
the graft islet -cell proliferation in pancreas was twofold
more vigorous in the pancreas than in the liver, as judged
by the percentage of BrdU
Insulin
 -cells in the graft
(P  0.01, Fig. 5B and D). Furthermore, we used sequential
CldU and IdU labeling to test whether the proliferation of
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FIG. 4. Long-term islet grafts in the pancreas maintained better
function than those in the liver. Islet grafts were retrieved from the
pancreas and liver, and the donor-type islets were identiﬁed with ex
vivo BLI. The expression levels of metabolic genes of -cells were
compared using donor islet-speciﬁc luciferase mRNA as an internal
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four replicate experiments is shown.
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described by Teta et al. (31). We found that the prolifer-
ating -cells in islet grafts were either CldU
 or IdU
, and
few were CldU
IdU
 (Fig. 5C and E). The percentage of
CldU
 or IdU
 insulin-secreting -cells in islet grafts from
the pancreas was nearly twofold higher than those from
the liver (P  0.01, Fig. 5C and E). These results indicate
that the proliferating -cells in islet grafts are from -cell
replication, but not neogenesis, and donor islet -cells
replicate better in the pancreas than in the liver.
Graft islets in the pancreas had higher vascular
density than in the liver. It has been reported that
revascularization of islets was important for graft islet
-cell proliferation and function (42–44). It was also
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A representative staining pattern of BrdU-labeling of proliferating -cells. C: A representative staining pattern of CldU and IdU-labeling of
replicating -cells. D: Mean  SE of percentage of proliferating -cells of 6 islet grafts in each group. E: Mean  SE of percentage of -cells from
replication or neogenesis of 4 islet grafts in each group. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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within 2–4 days and was completed by 14 days after islet
transplantation (45,46). Therefore, we compared the re-
vascularization of graft islets in the pancreas and in the
liver 3 weeks after transplantation. Accordingly, 3 weeks
after islet transplantation, graft islets were identiﬁed by in
vivo and ex vivo BLI and harvested as described in Fig. 5.
The sections of the selected pancreas tissues were stained
with the lectin Bandeiraea simplicifolia (BS-1) to visual-
ize blood vessels inside the graft islets as described
previously (37,38). We found that vascular density in the
graft islets from the pancreas was similar to the donor
islets before transplantation and was approximately four-
fold higher than in the graft islets from the liver (P  0.01,
Fig. 6). These results indicate that the better proliferation
and function of the graft islets in the pancreas than in the
liver may result from better intraislet revascularization of
graft islets in the pancreas.
No pancreatitis is induced by islet transplantation
into the pancreas. One major concern regarding implan-
tation of islets in the pancreas is induction of pancreatitis.
Therefore, we carefully compared the body weight and
serum amylase levels of the recipients with islet grafts in
the pancreas and liver. We found that all the recipients
with 300–600 islets in the pancreas or liver showed
healthy appearance, similar body weight, and little amy-
lase in their serum over an observation period of 120 days
(Fig. 7A and B).
DISCUSSION
We have demonstrated that compared with immunosup-
pressant therapy, induction of chimerism under the anti-
CD3-based conditioning regimen not only provided
immune tolerance to donor islets, but also markedly
reduced the required amount of donor islets for reversal of
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the pancreas of autoimmune diabetic recipients a better
site than the liver for donor islets, especially when small
amounts of donor islets were transplanted, which was
associated with better replication and long-term function
of donor islet -cells, as well as better revascularization of
the graft islets in the pancreas.
We observed that induction of chimerism markedly
reduced the required amount of donor islets for reversal of
severe late-stage type 1 diabetes. We found that with
immunosuppressants of the Edmonton protocol for pre-
vention of islet graft rejection, we needed to transplant
600 donor islets (3 donors) in the liver to reverse
diabetes. In contrast, as few as 100 donor islets implanted
in the liver (1⁄2 islets from a donor) were able to reverse
the disease after induction of chimerism. This is more than
a sixfold reduction. This required amount of donor islets
for reversal of diabetes in chimeric recipients is equivalent
to the required amount in syngeneic islet transplantation
in the liver as reported by others (47,48). In fact, trans-
plantation of donor islets into the recipients with donor
BM chimerism is similar to a syngeneic islet transplanta-
tion. Thus, the marked reduction of required donor islet
amount for reversal of diabetes in the chimeric recipients
is associated with avoidance of the immune rejection
mediated by allo- and autoimmunity, as well as the avoid-
ance of chemotoxicity to donor islets.
We also observed that induction of chimerism rendered
the pancreas of an autoimmune diabetic recipient a suit-
able site for donor islet grafts. It was shown that the
pancreas appears to be a better site than the liver for
donor islets in the syngeneic islet transplantation (15,16).
However, we found that under immunosuppressant ther-
apy for prevention of rejection, a large dose (1,000) of
donor islets that could reverse diabetes when implanted in
the liver failed to reverse diabetes when implanted in the
pancreas of the late-stage diabetic NOD mice. In contrast,
after induction of chimerism, a transplantation of as few as
25 islets into the pancreas was able to reverse the disease
in 40% of the recipients. This is a more than a 40-fold
reduction in the required amount of donor islets for
reversal of diabetes, as compared with immunosuppres-
sant therapy for prevention of rejection. One important
factor for induction of chimerism to render the pancreas a
suitable site for donor islets is the elimination of pre-
existing insulitis. Our previous studies have shown that
induction of chimerism not only prevented the recurrence
of autoimmunity, but also eliminated insulitis in the host
pancreas (2,27). This graft versus autoimmunity (GVA)
effect was mediated by donor CD8
 T-cells in the bone
marrow transplant, and this GVA effect was not associated
with GVHD in the recipients conditioned with anti-CD3–
based regimen as shown in our previous reports (27,29).
We observed that when small numbers of islets (i.e., less
than 100) were transplanted, islet grafts in the pancreas
were much more effective in reversing diabetes than in the
liver of the chimeric recipients. Furthermore, this differ-
ence resulted from better replication of graft islet -cells
early after transplantation and better long-term -cell
function in the pancreas than in the liver, which was
associated with improved revascularization of the graft
islets in the pancreas. It is not yet clear how graft islets in
the pancreas can have better revascularization and prolif-
eration than in the liver. It was reported that during
pregnancy in adult rats, insulin from islet -cells aug-
mented islet vascular endothelial cell proliferation, and in
turn, endothelial growth factor from the vascular endothe-
lial cells augmented -cell proliferation (44). Therefore, it
is possible that the existence of an endothelial-endocrine
axis in the pancreas favors -cell proliferation and islet
revascularization. In addition, the defective expression of
-cell functional genes of the graft islets in the liver of
long-term recipients may be caused by graft islets in the
liver (but not in the pancreas) that are chronically exposed
to high levels of glucose absorbed from the intestine and
produced by the hepatocytes that are toxic to islet
-cells (49).
There have been concerns that the differences in gene
expression proﬁles of islet grafts from the liver and
pancreas could be caused by the difference in purity of the
retrieved islets, as noted in a previous publication (15). In
the current study, this concern has been markedly re-
duced, if not eliminated. We used luciferase transgenic
donor islets for transplantation and we used luciferase
mRNA as baseline to avoid the impact of purity difference
in retrieved islets when we compared the gene expression
levels of the retrieved graft islets.
We are aware that it is still a concern that injection of
donor islets into the pancreas could potentially induce
pancreatitis in humans. However, we did not observe any
clinical signs of pancreatitis after injection of donor islets
into the mouse pancreas, because the bodyweight changes
and serum levels of amylase in the mouse recipients with
islet grafts in the pancreas or liver were similar. Reports by
others also showed that intrapancreatic injection of donor
islets in both rats and dogs did not induce pancreatitis
(16), and intrapancreatic injection of marrow stem cells in
humans did not induce pancreatitis either (50). Therefore,
it is possible that intrapancreatic injection of donor islets
in humans will not cause pancreatitis, and a nonhuman
primate trial is warranted to further test the feasibility.
In summary, we have demonstrated that induction of
chimerism under the radiation-free anti-CD3-based condi-
tioning regimen markedly reduces the required amount of
donor islets for reversal of late-stage diabetes and also
renders the pancreas of autoimmune diabetic recipients a
more suitable site for graft islets than the liver. Thus,
induction of chimerism under a nontoxic conditioning
regimen (i.e., anti-CD3-based conditioning) and implanta-
tion of donor islets into the pancreas of the chimeric
recipient may be a curative therapy in the future for
refractory late-stage type 1 diabetes.
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